ASX:IMM (Australia)  
Immutep Ltd logo

Immutep Ltd

A$ 0.35 (-2.82%) Dec 9
P/E:
At Loss
P/B:
3.17
Market Cap:
A$ 303.29M ($ 206.08M)
Enterprise V:
A$ 225.03M ($ 152.90M)
Volume:
859.47K
Avg Vol (2M):
1.23M
Also Trade In:
Volume:
859.47K
Market Cap A$:
303.29M
Market Cap $:
206.08M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.23M
Enterprise Value A$:
225.03M
Enterprise Value $:
152.90M
PB Ratio:
3.17

Business Description

Description
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its lead product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives most of the revenue from the sale of the products.
Name Current Vs Industry Vs History
Cash-To-Debt 46.16
Equity-to-Asset 0.92
Debt-to-Equity 0.02
Debt-to-EBITDA -0.05
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 18.95
Distress
Grey
Safe
Beneish M-Score 87.73
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 41.92
9-Day RSI 52.45
14-Day RSI 56.35
6-1 Month Momentum % -15.07
12-1 Month Momentum % -38

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 14.16
Quick Ratio 14.16
Cash Ratio 12.47
Days Sales Outstanding 2881.35

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -36.4